Table 1 Demographic data and laboratory values.
From: Characteristics, therapy, and outcome of rare functioning pancreatic neuroendocrine neoplasms
Patient No | Gender | Age at Dx | Age at initial surgery | Symptoms before surgery | Tumor localisation | Serum hormone elevated | Serum hormone level before first surgery elevated (x-fold)§ | CgA level before first surgery elevated (x-fold)§ |
|---|---|---|---|---|---|---|---|---|
1* | M | 31 | 32 | WDHA, abdominal pain | tail | VIP | 10-fold | NA |
2 | F | 61 | 73 | WDHA | tail | VIP | 2-fold | 2.6-fold |
3 | M | 60 | 70 | WDHA, weight loss | tail | VIP | 2.5-fold | 21.8-fold |
4 | F | 68 | 70 | abdominal pain | tail | calcitonin | 20.6-fold | 15-fold |
5 | M | 54 | 54 | abdominal pain | tail | calcitonin | 189-fold | NA |
6 | M | 69 | 69 | abdominal pain, weight loss | head | calcitonin | 16.5-fold | 2-fold |
7 | F | 66 | 66 | abdominal pain | tail | calcitonin | 17.6-fold | not elevated |
8 | F | 62 | 62 | diarrhea, abdominal pain | tail | calcitonin | 15-fold | 2.7-fold |
9 | F | 49 | 50 | NME, wasting, anemia | tail | glucagon | 46-fold | 56-fold |
10 | M | 66 | 66 | NME, foot and leg exanthem, weight loss, diarrhea | head | glucagon | 26.5-fold | 1.2-fold |
11 | M | 73 | 73 | diarrhea, nausea, vomiting | head | glucagon | 3-fold | 2.6-fold |
12 | M | 27 | 28 | diabetes mellitus, weight loss | tail | glucagon | 2.3-fold | not elevated |
